Child Kidney Dis.  2024 Feb;28(1):16-26. 10.3339/ckd.23.023.

Advances in the use of dried blood spots on filter paper to monitor kidney disease

• Nicola C
• Souza Vd

• KMID: 2553176
• DOI: http://doi.org/10.3339/ckd.23.023

Abstract

Patients with kidney disease require frequent blood tests to monitor their kidney function, which is particularly difficult for young children and the elderly. For these people, the standard method is to evaluate serum creatinine or cystatin C or drug levels through venous sampling, but more recently, evaluation using dried blood spots has been used. This narrative review reports information from the literature on the use of dried blood spots to quantify the main markers used to detect kidney diseases. The ScienceDirect and PubMed databases were searched using the keywords: “dried blood on filter paper,” “markers of renal function,” “renal function,” “creatinine,” “cystatin C,” “urea,” “iohexol,” and “iotalamate.” Studies using animal samples were excluded, and only relevant articles in English or Spanish were considered. Creatinine was the most assessed biomarker in studies using dried blood spots to monitor kidney function, showing good performance in samples whose hematocrit levels were within normal reference values. According to the included studies, dried blood spots are a practical monitoring alternative for kidney disease. Validation parameters, such as sample and card type, volume, storage, internal patterns, and the effects of hematocrit are crucial to improving the reliability of these results.

Keyword

Creatinine; Cystatin C; Dried blood spot testing; Iohexol; Urea

Reference

References

1. Bikbov B, Perico N, Remuzzi G; on behalf of the GBD Genitourinary Diseases Expert Group. Disparities in chronic kidney disease prevalence among males and females in 195 countries: analysis of the global burden of disease 2016 study. Nephron. 2018; 139:313–8.

2. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96:414–422D.

3. World Health Organization (WHO). The top 10 causes of death [Internet]. WHO;2020. [cited 2023 Nov 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

4. Byrne C, Cove-Smith A. Clinical assessment of renal disease. Medicine. 2019; 47:475–81.

5. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018; 2018:2180373.

6. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382:260–72.

7. Biljak VR, Honovic L, Matica J, Kresic B, Vojak SS. The role of laboratory testing in detection and classification of chronic kidney disease: national recommendations. Biochem Med (Zagreb). 2017; 27:153–76.

8. Wang YN, Ma SX, Chen YY, Chen L, Liu BL, Liu QQ, et al. Chronic kidney disease: biomarker diagnosis to therapeutic targets. Clin Chim Acta. 2019; 499:54–63.

9. Rysz J, Gluba-Brzozka A, Franczyk B, Jablonowski Z, Cialkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci. 2017; 18:1702.

10. Lamb E. Assessment of kidney function in adults. Medicine. 2015; 43:368–73.

11. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evalua­tion and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1–150.

12. Soares AA. Ferramentas para detecção da doença renal: valores de referência da taxa de filtração glomerular e desempenho das equações de estimativa com creatinina e cistatina C séricas em indivíduos saudáveis [doctor’s thesis]. Postgraduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS);2013.

13. Silva AC, Gomez JF, Lugon JR, Graciano ML. Creatinine measurement on dry blood spot sample for chronic kidney disease screening. J Bras Nefrol. 2016; 38:15–21.

14. Enderle Y, Foerster K, Burhenne J. Clinical feasibility of dried blood spots: analytics, validation, and applications. J Pharm Biomed Anal. 2016; 130:231–43.

15. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 2010; 12:290–3.

16. Lakshmy R. Analysis of the use of dried blood spot measurements in disease screening. J Diabetes Sci Technol. 2008; 2:242–3.

17. Gupta K, Mahajan R. Applications and diagnostic potential of dried blood spots. Int J Appl Basic Med Res. 2018; 8:1–2.

18. Sharma A, Jaiswal S, Shukla M, Lal J. Dried blood spots: concepts, present status, and future perspectives in bioanalysis. Drug Test Anal. 2014; 6:399–414.

19. Velghe S, Delahaye L, Stove CP. Is the hematocrit still an issue in quantitative dried blood spot analysis? J Pharm Biomed Anal. 2019; 163:188–96.

20. Shahbaz H, Gupta M. Creatinine clearance. In: StatPearls [Internet]. StatPearls Publishing; 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/31334948/.

21. Sodre FL, Costa JCB, Lima JCC. Evaluation of renal function and damage: a laboratorial challenge. J Bras Patol Med Lab. 2007; 43:329–37.

22. Bruck K, Jager KJ, Dounousi E, Kainz A, Nitsch D, Arnlov J, et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015; 30 Suppl 4(Suppl 4):iv6–16.

23. George JA, Gounden V. Novel glomerular filtration markers. Adv Clin Chem. 2019; 88:91–119.

24. Hocher B, Adamski J. Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol. 2017; 13:269–84.

25. Bjornstad P, Anderson PL, Maahs DM. Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. Acta Diabetol. 2016; 53:331–3.

26. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963; 32:338–43.

27. Meesters RJ, Hooff GP. State-of-the-art dried blood spot analysis: an overview of recent advances and future trends. Bioanalysis. 2013; 5:2187–208.

28. Castro AC, Borges LG, Souza Rda S, Grudzinski M, D'Azevedo PA. Evaluation of the human immunodeficiency virus type 1 and 2 antibodies detection in dried whole blood spots (DBS) samples. Rev Inst Med Trop Sao Paulo. 2008; 50:151–6.

29. Lehmann S, Delaby C, Vialaret J, Ducos J, Hirtz C. Current and future use of "dried blood spot" analyses in clinical chemistry. Clin Chem Lab Med. 2013; 51:1897–909.

30. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009; 31:327–36.

31. Koster RA, Alffenaar JW, Botma R, Greijdanus B, Touw DJ, Uges DR, et al. What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis? Bioanalysis. 2015; 7:345–51.

32. Koster RA, Greijdanus B, Alffenaar JW, Touw DJ. Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Anal Bioanal Chem. 2015; 407:1585–94.

33. Lim MD. Dried blood spots for global health diagnostics and surveillance: opportunities and challenges. Am J Trop Med Hyg. 2018; 99:256–65.

34. Crimmins EM, Zhang YS, Kim JK, Frochen S, Kang H, Shim H, et al. Dried blood spots: effects of less than optimal collection, shipping time, heat, and humidity. Am J Hum Biol. 2020; 32:e23390.

35. Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019; 41:409–30.

36. Denniff P, Woodford L, Spooner N. Effect of ambient humidity on the rate at which blood spots dry and the size of the spot produced. Bioanalysis. 2013; 5:1863–71.

37. Prentice P, Turner C, Wong MC, Dalton RN. Stability of metabolites in dried blood spots stored at different temperatures over a 2-year period. Bioanalysis. 2013; 5:1507–14.

38. Malsagova K, Kopylov A, Stepanov A, Butkova T, Izotov A, Kaysheva A. Dried blood spot in laboratory: directions and prospects. Diagnostics (Basel). 2020; 10:248.

39. Al-Uzri A, Freeman KA, Wade J, Clark K, Bleyle LA, Munar M, et al. Longitudinal study on the use of dried blood spots for home monitoring in children after kidney transplantation. Pediatr Transplant. 2017; 21:e12983.

40. Vogl PT. Measurement of cystatin C in dried blood spot specimens [master’s thesis]. University of Washington;2013.

41. Salvador CL, Tondel C, Morkrid L, Bjerre A, Brun A, Bolann B, et al. Glomerular filtration rate measured by iohexol clearance: a comparison of venous samples and capillary blood spots. Scand J Clin Lab Invest. 2015; 75:710–6.

42. Staples A, Wong C, Schwartz GJ. Iohexol-measured glomerular filtration rate in children and adolescents with chronic kidney disease: a pilot study comparing venous and finger stick methods. Pediatr Nephrol. 2019; 34:459–64.

43. Dalton RN, Isbell TS, Ferguson R, Fiore L, Malic A, DuBois JA. Creatinine standardization: a key consideration in evaluating whole blood creatinine monitoring systems for CKD screening. Anal Bioanal Chem. 2022; 414:3279–89.

44. Koster RA, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ, et al. The performance of five different dried blood spot cards for the analysis of six immunosuppressants. Bioanalysis. 2015; 7:1225–35.

45. Timmerman P, White S, Cobb Z, de Vries R, Thomas E, van Baar B, et al. Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium. Bioanalysis. 2013; 5:2129–36.

46. Timmerman P, White S, Globig S, Ludtke S, Brunet L, Smeraglia J. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis. 2011; 3:1567–75.

47. Daousani C, Karalis V, Malenovic A, Dotsikas Y. Hematocrit effect on dried blood spots in adults: a computational study and theoretical considerations. Scand J Clin Lab Invest. 2019; 79:325–33.

48. Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014; 53:961–73.

49. Koster RA, Alffenaar JW, Botma R, Greijdanus B, Uges DR, Kosterink JG, et al. The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. Bioanalysis. 2015; 7:1717–22.

50. den Burger JC, Wilhelm AJ, Chahbouni AC, Vos RM, Sinjewel A, Swart EL. Haematocrit corrected analysis of creatinine in dried blood spots through potassium measurement. Anal Bioanal Chem. 2015; 407:621–7.

51. Abu-Rabie P, Denniff P, Spooner N, Chowdhry BZ, Pullen FS. Investigation of different approaches to incorporating internal standard in DBS quantitative bioanalytical workflows and their effect on nullifying hematocrit-based assay bias. Anal Chem. 2015; 87:4996–5003.

52. Reyes-Garces N, Alam MN, Pawliszyn J. The effect of hematocrit on solid-phase microextraction. Anal Chim Acta. 2018; 1001:40–50.

53. Hagan AS, Jones DR, Agarwal R. Use of dried plasma spots for the quantification of iothalamate in clinical studies. Clin J Am Soc Nephrol. 2013; 8:909–14.

54. Scribel L, Zavascki AP, Matos D, Silveira F, Peralta T, Goncalves Landgraf N, et al. Vancomycin and creatinine determination in dried blood spots: analytical validation and clinical assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2020; 1137:121897.

55. Anibaletto Dos Santos AL, Cezimbra da Silva AC, Feltraco Lizot LL, Schneider A, Meireles YF, Hahn RZ, et al. Development and validation of an assay for the measurement of gentamicin concentrations in dried blood spots using UHPLC-MS/MS. J Pharm Biomed Anal. 2022; 208:114448.

56. Quraishi R, Lakshmy R, Mukhopadhyay AK, Jailkhani BL. Creatinine measurement and stability in dried serum. J Diabetes Sci Technol. 2012; 6:988–9.

57. Abraham RA, Kapil U, Aggarwal SK, Pandey RM, Sharma M, Ramakrishnan L. Measurement of creatinine from dried blood spot by enzymatic method. Int J Adv Res Chem Sci. 2015; 2:42–6.

58. Nakano M, Uemura O, Honda M, Ito T, Nakajima Y, Saitoh S. Development of tandem mass spectrometry-based creatinine measurement using dried blood spot for newborn mass screening. Pediatr Res. 2017; 82:237–43.

59. Bachini FI, Pereira D, Santos R, Hausen M, Pereira G, Vieira C, et al. Creatine and creatinine quantification in olympic athletes: dried blood spot analysis pilot study. Biol Sport. 2022; 39:745–9.

60. Sham TT, Badu-Tawiah AK, McWilliam SJ, Maher S. Assessment of creatinine concentration in whole blood spheroids using paper spray ionization-tandem mass spectrometry. Sci Rep. 2022; 12:14308.

61. Crimmins E, Kim JK, McCreath H, Faul J, Weir D, Seeman T. Validation of blood-based assays using dried blood spots for use in large population studies. Biodemography Soc Biol. 2014; 60:38–48.

62. Plumbe RM, Worth HG. Dried blood spot test estimation of urea. Ann Clin Biochem. 1985; 22(Pt 4):408–11.

63. Quraishi R, Lakshmy R, Mukhopadhyay AK, Jailkhani BL. Analysis of the stability of urea in dried blood spots collected and stored on filter paper. Ann Lab Med. 2013; 33:190–2.

64. Selistre LS, Cochat P, Rech D, Parant F, Souza VCD, Dubourg L. Associação entre taxa de filtração glomerular (medida por cromatografia liquida de alto desempenho com iohexol) e oxalato plasmático. J Bras Nephrol. 2018; 40:73–6.

65. Niculescu-Duvaz I, D'Mello L, Maan Z, Barron JL, Newman DJ, Dockrell ME, et al. Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies. Kidney Int. 2006; 69:1272–5.

66. Mafham MM, Niculescu-Duvaz I, Barron J, Emberson JR, Dockrell ME, Landray MJ, et al. A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots. Nephron Clin Pract. 2007; 106:c104–12.

67. Maahs DM, Bushman L, Kerr B, Ellis SL, Pyle L, McFann K, et al. A practical method to measure GFR in people with type 1 diabetes. J Diabetes Complications. 2014; 28:667–73.

68. Wang BB, Wu Y, Qin Y, Gong MC, Shi XM, Jing HL, et al. Application of plasma clearance of iohexol in evaluating renal function in Chinese children with chronic kidney disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015; 37:171–8.

69. Luis-Lima S, Gaspari F, Negrin-Mena N, Carrara F, Diaz-Martin L, Jimenez-Sosa A, et al. Iohexol plasma clearance simplified by dried blood spot testing. Nephrol Dial Transplant. 2018; 33:1597–603.

70. Wu H, Huang J. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018; 19:559–67.

71. Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clin J Am Soc Nephrol. 2022; 17:1220–33.

72. Pinto PS, Carminatti M, Lacet T, Rodrigues DF, Nogueira LO, Bastos MG, et al. Nephrotoxic acute renal failure: prevalence, clinical course and outcome. J Bras Nephrol. 2009; 31:183–9.

73. Calvo DM, Saiz LC, Leache L, Celaya MC, Gutierrez-Valencia M, Alonso A, et al. Effect of the combination of diuretics, renin-angiotensin-aldosterone system inhibitors, and non-steroidal anti-inflammatory drugs or metamizole (triple whammy) on hospitalisation due to acute kidney injury: a nested case-control study. Pharmacoepidemiol Drug Saf. 2023; 32:898–909.

74. Scherf-Clavel M, Albert E, Zieher S, Valotis A, Hickethier T, Hogger P. Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. Eur J Clin Pharmacol. 2019; 75:809–16.

75. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018; 13:1085–95.

76. Scherf-Clavel M, Hogger P. Analysis of metformin, sitagliptin and creatinine in human dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 997:218–28.

77. Mathew BS, Mathew SK, Aruldhas BW, Prabha R, Gangadharan N, David VG, et al. Analytical and clinical validation of dried blood spot and volumetric absorptive microsampling for measurement of tacrolimus and creatinine after renal transplantation. Clin Biochem. 2022; 105-106:25–34.

78. Koop DR, Bleyle LA, Munar M, Cherala G, Al-Uzri A. Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 926:54–61.

79. Francke MI, van Domburg B, Bouarfa S, van de Velde D, Hellemons ME, Manintveld OC, et al. The clinical validation of a dried blood spot method for simultaneous measurement of cyclosporine A, tacrolimus, creatinine, and hematocrit. Clin Chim Acta. 2022; 535:131–9.

80. Veenhof H, Koster RA, Alffenaar JC, Berger SP, Bakker SJ, Touw DJ. Clinical validation of simultaneous analysis of tacrolimus, cyclosporine A, and creatinine in dried blood spots in kidney transplant patients. Transplantation. 2017; 101:1727–33.

81. Tan SJ, Cockcroft M, Page-Sharp M, Arendts G, Davis TM, Moore BR, et al. Population pharmacokinetic study of ceftriaxone in elderly patients, using cystatin C-based estimates of renal function to account for frailty. Antimicrob Agents Chemother. 2020; 64:e00874–20.

82. Cheung CY, van der Heijden J, Hoogtanders K, Christiaans M, Liu YL, Chan YH, et al. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int. 2008; 21:140–5.

83. Almardini R, Taybeh EO, Alsous MM, Hawwa AF, McKeever K, Horne R, et al. A multiple methods approach to determine adherence with prescribed mycophenolate in children with kidney transplant. Br J Clin Pharmacol. 2019; 85:1434–42.